Last reviewed · How we verify
Crodimyl — Competitive Intelligence Brief
phase 2
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Crodimyl (METHYLCHROMONE). Crodimyl works by modulating the activity of a specific cellular pathway to improve blood flow to the heart.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Crodimyl TARGET | METHYLCHROMONE | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Crodimyl — Competitive Intelligence Brief. https://druglandscape.com/ci/methylchromone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing